|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 311.00 SEK | +0.19% |
|
-5.47% | +0.06% |
| 15/01 | 19 Stocks Reach New 52-Week Highs Today on the Stockholm Stock Exchange | FW |
| 15/01 | Biogen CEO: At-Home Alzheimer's Treatment Could Give Edge Over Lilly's Version - BN | FW |
| Capitalization | 46.18B 5.13B 4.36B 4.04B 3.78B 7.04B 471B 7.46B 18.33B 222B 19.22B 18.83B 809B | P/E ratio 2025 * |
26.6x | P/E ratio 2026 * | 93.8x |
|---|---|---|---|---|---|
| Enterprise value | 44.15B 4.9B 4.17B 3.86B 3.61B 6.73B 450B 7.13B 17.53B 213B 18.37B 18B 773B | EV / Sales 2025 * |
21.9x | EV / Sales 2026 * | 36.8x |
| Free-Float |
44.08% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BioArctic AB
| 1 day | +0.19% | ||
| 1 week | -5.47% | ||
| Current month | +0.06% | ||
| 1 month | -2.87% | ||
| 3 months | +6.65% | ||
| 6 months | +41.49% | ||
| Current year | +0.06% |
| 1 week | 284 |  | 319.6 |
| 1 month | 284 | | 347.6 |
| Current year | 284 | | 347.6 |
| 1 year | 154.4 | | 347.6 |
| 3 years | 137.7 | | 392 |
| 5 years | 66.7 | | 392 |
| 10 years | 20.4 | | 392 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/01/2013 | |
| Director of Finance/CFO | 55 | 01/06/2023 | |
Johanna Fälting
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/01/2012 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 79 | 24/01/2003 | |
| Chairman | 77 | 28/01/2003 | |
Eugen Steiner
CHM | Chairman | 72 | 01/06/2023 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +3.83% | 1.25% | 4 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.19% | -5.47% | +55.50% | -2.32% | 5.13B | |
| +0.04% | -0.68% | -4.77% | +12.20% | 49.48B | |
| -1.56% | -1.00% | +14.23% | +2.87% | 40.07B | |
| +0.15% | +0.33% | +52.68% | +26.14% | 37.55B | |
| +1.92% | +1.44% | +23.10% | +42.46% | 31.67B | |
| -0.99% | -2.20% | +185.93% | +328.06% | 22.74B | |
| -3.01% | -3.74% | +69.03% | +145.51% | 16.56B | |
| Average | -0.47% | -1.17% | +56.53% | +79.27% | 29.03B | |
| Weighted average by Cap. | -0.32% | -0.41% | +42.82% | +63.50% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.02B 224M 190M 176M 165M 307M 20.55B 326M 800M 9.7B 839M 822M 35.29B | 1.2B 134M 114M 105M 98.49M 184M 12.28B 195M 478M 5.8B 501M 491M 21.1B |
| Net income | 1B 112M 94.84M 87.91M 82.15M 153M 10.25B 162M 399M 4.84B 418M 410M 17.6B | 294M 32.65M 27.77M 25.74M 24.05M 44.83M 3B 47.52M 117M 1.42B 122M 120M 5.15B |
| Net Debt | -2.03B -225M -192M -178M -166M -309M -20.69B -328M -805M -9.77B -844M -827M -35.53B | -1.8B -200M -170M -158M -147M -274M -18.36B -291M -715M -8.67B -749M -734M -31.54B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 311.00 kr | +0.19% | 115,718 |
| 22/01/26 | 310.40 kr | +4.94% | 212,714 |
| 21/01/26 | 295.80 kr | +0.14% | 194,759 |
| 20/01/26 | 295.40 kr | -5.68% | 447,741 |
| 19/01/26 | 313.20 kr | -4.80% | 235,233 |
Delayed Quote Nasdaq Stockholm, 24 January 2026 at 04:00 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIOA B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition